Sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg [Vosevi]
RxNorm 1939331

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1939331 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg [Vosevi].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg [Vosevi]
AUI:9243974
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Sofosbuvir 400 mg / velpatasvir 100 mg / voxilaprevir 100 mg [Vosevi]
(Atom ID: 9243974)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG [Vosevi]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1939331
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
9243974
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1939331
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Sofosbuvir, Velpatasvir, and Voxilaprevir


The combination of sofosbuvir, velpatasvir, and voxilaprevir is used to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in adults who have already received other HCV treatments. Sofosbuvir is a non-nucleoside NS5B polymerase inhibitor. It works by decreasing the amount of hepatitis C virus in the body. Velpatasvir is a hepatitis C virus (HCV) NS5A inhibitor. It works by stopping the virus that causes hepatitis C from spreading inside the body. Voxilaprevir is in a class of medications called HCV NS3/4A protease inhibitors. It works by decreasing the amount of HCV in the body.
[Learn More]


* Please review the disclaimer below.